Microbiome-Based Hypothesis on Ivermectin’s Mechanism in COVID-19: Ivermectin Feeds Bifidobacteria to Boost Immunity
Sabine Hazan
Frontiers in Microbiology, doi:10.3389/fmicb.2022.952321
Ivermectin is an anti-parasitic agent that has gained attention as a potential COVID-19 therapeutic. It is a compound of the type Avermectin, which is a fermented by-product of Streptomyces avermitilis. Bifidobacterium is a member of the same phylum as Streptomyces spp., suggesting it may have a symbiotic relation with Streptomyces. Decreased Bifidobacterium levels are observed in COVID-19 susceptibility states, including old age, autoimmune disorder, and obesity. We hypothesize that Ivermectin, as a by-product of Streptomyces fermentation, is capable of feeding Bifidobacterium, thereby possibly preventing against COVID-19 susceptibilities. Moreover, Bifidobacterium may be capable of boosting natural immunity, offering more direct COVID-19 protection. These data concord with our study, as well as others, that show Ivermectin protects against COVID-19.
AUTHOR CONTRIBUTIONS The author confirms being the sole contributor of this work and has approved it for publication. Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher. Copyright © 2022 Hazan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
References
Abbas, Muhammad, Ding, The effect of ivermectin on reducing viral symptoms in patients with mild COVID-19
Abd-Elsalam, Noor, Badawi, Khalaf, Esmail et al., Clinical study evaluating the efficacy of ivermectin in COVID-19 treatment: a randomized controlled study, J. Med. Virol,
doi:10.1002/jmv.27122Ahmed, Karim, Ross, Hossain, Clemens et al., A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness, Int. J. Infect. Dis,
doi:10.1016/j.ijid.2020.11.191Ahsan, Rani, Siddiqui, D'souza, Memon et al., Clinical variants, characteristics, and outcomes among COVID-19 patients: a case series analysis at a tertiary care hospital in Karachi, Pakistan,
doi:10.7759/cureus.14761Alam, Murshed, Gomes, Masud, Saber et al., Ivermectin as pre-exposure prophylaxis for COVID-19 among healthcare providers in a selected tertiary hospital in Dhaka -an observational study, Eur. J. Med. Health Sci,
doi:10.24018/ejmed.2020.2.6.599Aref, Bazeed, Hassan, Hassan, Rashad et al., Clinical, biochemical and molecular evaluations of ivermectin mucoadhesivenanosuspension nasal spray in reducing upper respiratory symptoms of mild COVID-19, Int. J. Nanomed,
doi:10.2147/IJN.S313093Ascencio-Montiel, Tomás-López, Álvarez-Medina, Gil-Velázquez, Vega-Vega et al., A multimodal strategy to reduce the risk of hospitalization/death in ambulatory patients with COVID-19, Arch. Med. Res,
doi:10.1016/j.arcmed.2022.01.002Babalola, Bode, Ajayi, Alakaloko, Akase et al., Ivermectin shows clinical benefits in mild to moderate COVID19: a randomized controlled double-blind, dose-response study in Lagos, QJM Int. J. Med,
doi:10.1093/qjmed/hcab035Barton, Nakanishi, Meth-Cohn, Comprehensive Natural Products Chemistry
Behera, Patro, Singh, Chandanshive, Ravikumar et al., Role of ivermectin in the prevention of SARS-CoV-2 infection among healthcare workers in India: a matched case-control study, PLoS One,
doi:10.1371/journal.pone.0247163Beltran Gonzalez, González Gámez, Mendoza Enciso, Esparza Maldonado, Hernández Palacios et al., Efficacy and safety of ivermectin and hydroxychloroquine in patients with severe COVID-19: a randomized controlled trial, Infect. Dis. Rep,
doi:10.3390/idr14020020Bernstein, Cha, Second-Week Crash' is Time of Peril for Some Covid-19 Patients
Bozkurt, Quigley, The probiotic Bifidobacterium in the management of Coronavirus: a theoretical basis, Int. J. Immunopathol. Pharmacol,
doi:10.1177/2058738420961304Buonfrate, Chesini, Martini, Roncaglioni, Ojeda Fernandez et al., High-dose ivermectin for early treatment of COVID-19 (COVER study): a randomised, double-blind, multicentre, phase II, dosefinding, proof-of-concept clinical trial, Int. J. Antimicrob. Agents,
doi:10.1016/j.ijantimicag.2021.106516Cadegiani, Goren, Wambier, Mccoy, Early COVID-19 therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in outpatient settings significantly improved COVID-19 outcomes compared to known outcomes in untreated patients, New Microbes New Infect,
doi:10.1016/j.nmni.2021.100915Chaccour, Casellas, Blanco-Di Matteo, Pineda, Fernandez-Montero et al., The effect of early treatment with Hazan Ivermectin Feeds Bifidobacterium Fighting COVID-19
Chahla, Medina Ruiz, Ortega, Morales Rn, Barreiro et al., Intensive treatment with ivermectin and iota-carrageenan as pre-exposure prophylaxis for COVID-19 in health care workers from Tucuman, Argentina, Am. J. Ther,
doi:10.1097/MJT.0000000000001433Chowdhury, Shahbaz, Karim, Islam, Dan et al., A comparative study on ivermectin-doxycycline and hydroxychloroquine-azithromycin therapy on COVID-19 patients, Eurasian J. Med. Oncol,
doi:10.14744/ejmo.2021.16263Conte, Toraldo, Targeting the gut-lung microbiota axis by means of a high-fibre diet and probiotics may have anti-inflammatory effects in COVID-19 infection, Ther. Adv. Respir. Dis,
doi:10.1177/1753466620937170De, Vuyst, Moens, Selak, Rivière et al., Summer Meeting 2013: growth and physiology of bifidobacteria, J. Appl. Microbiol,
doi:10.1111/JAM.12415Dyakov, Mavletova, Chernyshova, Snegireva, Gavrilova et al., FN3 protein fragment containing two type III fibronectin domains from B. longum GT15 binds to human tumor necrosis factor alpha in vitro, Anaerobe,
doi:10.1016/J.ANAEROBE.2020.102247Elalfy, Besheer, El-Mesery, El-Gilany, Soliman et al., Effect of a combination of nitazoxanide, ribavirin, and ivermectin plus zinc supplement (MANS.NRIZ study) on the clearance of mild COVID-19, J. Med. Virol,
doi:10.1002/jmv.26880Faisal, Shah, Hussain, Potential use of azithromycin alone and in combination with ivermectin in fighting against the symptoms of COVID-19, Prof. Med. J,
doi:10.29309/TPMJ/2021.28.05.5867Ferreira, Beranger, Sampaio, Mansur Filho, Lima, Outcomes associated with Hydroxychloroquine and Ivermectin in hospitalized patients with COVID-19: a single-center experience, Rev. Assoc. Médica Bras,
doi:10.1590/1806-9282.20210661Gavriatopoulou, Ntanasis-Stathopoulos, Korompoki, Fotiou, Migkou et al., Emerging treatment strategies for COVID-19 infection, Clin. Exp. Med,
doi:10.1007/s10238-020-00671-yGutiérrez-Castrellón, Gandara-Martí, Abreu, Abreu, Nieto-Rufino et al., Probiotic improves symptomatic and viral clearance in Covid19 outpatients: a randomized, quadruple-blinded, placebo-controlled trial, Gut Microbes,
doi:10.1080/19490976.2021.2018899Hazan, Dave, Gunaratne, Dolai, Clancy et al., Effectiveness of ivermectin-based multidrug therapy in severely hypoxic, ambulatory COVID-19 patients, Future Microbiol,
doi:10.2217/FMB-2022-0014Hazan, Stollman, Bozkurt, Dave, Papoutsis et al., Lost microbes of COVID-19: Bifidobacterium,Faecalibacterium depletion and decreased microbiome diversity associated with SARS-CoV-2 infection severity, BMJ Open Gastroenterol,
doi:10.1136/bmjgast-2022-000871Heidary, Gharebaghi, Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen, J. Antibiot,
doi:10.1038/s41429-020-0336-zHughes, Harnisch, Alcon-Giner, Mitra, Wright et al., Bifidobacterium breve reduces apoptotic epithelial cell shedding in an exopolysaccharide and MyD88-dependent manner, Open Biol,
doi:10.1098/RSOB.160155Jabczyk, Nowak, Hudzik, Zubelewicz-Szkodzińska, Diet, probiotics and their impact on the gut microbiota during the COVID-19 pandemic, Nutrients,
doi:10.3390/NU13093172Joshi, Borah, Thakur, Sharma, Mayank et al., Exploring the COVID-19 vaccine candidates against SARS-CoV-2 and its variants: where do we stand and where do we go?, Hum. Vaccines Immunother,
doi:10.1080/21645515.2021.1995283Kerr, Cadegiani, Baldi, Lobo, Assagra et al., Ivermectin prophylaxis used for COVID-19: a citywide, prospective, observational study of 223,128 subjects using propensity score matching, Cureus,
doi:10.7759/cureus.21272Khan, Khan, Debnath, Nath, Mahtab et al., Ivermectin treatment may improve the prognosis of patients with COVID-19, Arch. Bronconeumol,
doi:10.1016/j.arbres.2020.08.007Khodavirdipour, Asadimanesh, Masoumi, Impact of SARS-CoV-2 genetic blueprints on the oral manifestation of COVID-19: a case report, Glob. Med. Genet,
doi:10.1055/s-0041-1735538Khodavirdipour, Chamanrokh, Alikhani, Alikhani, Potential of Bacillus subtilis against SARS-CoV-2 -a sustainable drug development perspective, Front. Microbiol,
doi:10.3389/fmicb.2022.718786Khodavirdipour, Inclusion of cephalexin in COVID-19 treatment combinations may prevent lung involvement in mild infections: a case report with pharmacological genomics perspective, Glob. Med. Genet,
doi:10.1055/s-0041-1726461Khodavirdipour, Jabbari, Keramat, Alikhani, Concise update on genomics of COVID-19: approach to its latest mutations, escalated contagiousness, and vaccine resistance, Glob. Med. Genet,
doi:10.1055/s-0041-1725143Khodavirdipour, Keramat, Hamid Hashemi, Yousefalikhani, SARS-CoV-2; from vaccine development to drug discovery and prevention guidelines, AIMS Mol. Sci,
doi:10.3934/molsci.2020013Khodavirdipour, Piri, Jabbari, Khalaj-Kondori, Potential of CRISPR/Cas13 system in treatment and diagnosis of COVID-19, Glob. Med. Genet,
doi:10.1055/s-0041-1723086Kinobe, Owens, A systematic review of experimental evidence for antiviral effects of ivermectin and an in silico analysis of ivermectin's possible mode of action against SARS-CoV-2, Fundam. Clin. Pharmacol,
doi:10.1111/fcp.12644Kishoria, Mathur, Parmar, Kaur, Agarwal et al., Ivermectin as adjuvant to hydroxycholoroquine in patients resistant to standard treatment for Sars-Cov-2: results of an open-label randomized clinical study, Paripex Indian J. Res,
doi:10.36106/paripex/4801859Krolewiecki, Lifschitz, Moragas, Travacio, Valentini et al., Antiviral effect of high-dose ivermectin in adults with COVID-19: a proof-of-concept randomized trial, eClinicalMedicine,
doi:10.1016/j.eclinm.2021.100959Lazarenko, Babenko, Sichel, Pidgorskyi, Mokrozub et al., antagonistic action of lactobacilli and bifidobacteria in relation to Staphylococcus aureus and their influence on the immune response in cases of intravaginal Staphylococcosis in mice, Probiotics Antimicrob. Proteins,
doi:10.1007/s12602-012-9093-zLehrer, Rheinstein, Ivermectin docks to the SARS-CoV-2 spike receptor-binding domain attached to ACE2, Vivo,
doi:10.21873/invivo.12134Lim, Hor, Tay, Mat, Jelani et al., Efficacy of ivermectin treatment on disease progression among adults with mild to moderate COVID-19 and comorbidities: the I-TECH randomized clinical trial, JAMA Intern. Med,
doi:10.1001/jamainternmed.2022.0189Lim, Shin, Antimicrobial and immunomodulatory effects of Bifidobacterium strains: a review, J. Microbiol. Biotechnol,
doi:10.4014/JMB.2007.07046Lima-Morales, Méndez-Hernández, Flores, Osorno-Romero, Sancho-Hernández et al., Effectiveness of a multidrug therapy consisting of Ivermectin, Azithromycin, Montelukast, and Acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico, Int. J. Infect. Dis,
doi:10.1016/j.ijid.2021.02.014López-Medina, López, Hurtado, Dávalos, Ramirez et al., Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: a randomized clinical trial, JAMA,
doi:10.1001/jama.2021.3071Markowiak, Śliżewska, Effects of probiotics, prebiotics, and synbiotics on human health, Nutrients,
doi:10.3390/nu9091021Mayer, Krolewiecki, Ferrero, Bocchio, Barbero et al., Safety and efficacy of a MEURI program for the use of high dose ivermectin in COVID-19 patients, Front. Public Health,
doi:10.3389/fpubh.2022.813378Mohan, Tiwari, Suri, Mittal, Patel et al., Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): a single-centre randomized, placebo-controlled trial, J. Infect. Chemother,
doi:10.1016/j.jiac.2021.08.021Molyneux, Ward, Reflections on the nobel prize for medicine 2015 -the public health legacy and impact of Avermectin and Artemisinin, Trends Parasitol,
doi:10.1016/j.pt.2015.10.008Morgenstern, Redondo, Olavarria, Rondon, Roca et al., Ivermectin as a SARS-CoV-2 pre-exposure prophylaxis method in healthcare workers: a propensity score-matched retrospective cohort study, Cureus,
doi:10.7759/cureus.17455Mukarram, Ivermectin use associated with reduced duration of Covid-19 febrile illness in a community setting, Int. J. Clin. Stud. Med. Case Rep,
doi:10.46998/IJCMCR.2021.13.000320Mustafa, Kow, Salman, Kanwal, Riaz et al., Pattern of medication utilization in hospitalized patients with COVID-19 in three District Headquarters Hospitals in the Punjab province of Pakistan, Explor. Res. Clin. Soc. Pharm,
doi:10.1016/j.rcsop.2021.100101Okumuş, Demirtürk, Çetinkaya, Güner, Avcı et al., Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients, BMC Infect. Dis,
doi:10.1186/s12879-021-06104-9Ozer, Goksu, Conception, Ulker, Balderas et al., Effectiveness and safety of Ivermectin in COVID-19 patients: a prospective study at a safety-net hospital, J. Med. Virol,
doi:10.1002/jmv.27469Podder, Chowdhury, Sina, Haque, Outcome of ivermectin treated mild to moderate COVID-19 cases: a singlecentre, open-label, randomised controlled study, IMC J. Med. Sci,
doi:10.3329/imcjms.v14i2.52826Rajter, Sherman, Fatteh, Vogel, Sacks et al., Use of ivermectin is associated with lower mortality in hospitalized patients with Coronavirus disease, Chest,
doi:10.1016/j.chest.2020.10.009Ravikirti, Pattadar, Raj, Agarwal, Biswas, Evaluation of ivermectin as a potential treatment for mild to moderate COVID-19: a double-blind randomized placebo controlled trial in Eastern India, J. Pharm. Pharm. Sci,
doi:10.18433/jpps32105Reaz, Rahman, Iftikher, Ahmed, Kabir et al., Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial, J. Int. Med. Res,
doi:10.5061/DRYAD.QJQ2BVQF6Reinold, Farahpour, Fehring, Dolff, Konik et al., A pro-inflammatory gut microbiome characterizes SARS-CoV-2 infected patients and a reduction in the connectivity of an anti-inflammatory bacterial network associates with severe COVID-19, Front. Cell. Infect. Microbiol,
doi:10.3389/fcimb.2021.747816Reis, Silva, Silva, Thabane, Milagres et al., Effect of early treatment with ivermectin among patients with Covid-19, N. Engl. J. Med,
doi:10.1056/NEJMoa2115869Rezk, Elsayedsileem, Gad, Khalil, miRNA-223-3p, miRNA-2909 and cytokines expression in COVID-19 patients treated with ivermectin, Zagazig Univ. Med. J,
doi:10.21608/zumj.2021.92746.2329Rivière, Selak, Lantin, Leroy, Vuyst, Bifidobacteria and butyrate-producing colon bacteria: importance and strategies for their stimulation in the human gut, Front. Microbiol,
doi:10.3389/fmicb.2016.00979Rizzo, Ivermectin, antiviral properties and COVID-19: a possible new mechanism of action, Naunyn. Schmiedebergs Arch. Pharmacol,
doi:10.1007/s00210-020-01902-5Ruiz, Delgado, Ruas-Madiedo, Sánchez, Margolles, Bifidobacteria and their molecular communication with the immune system, Front. Microbiol,
doi:10.3389/fmicb.2017.02345Seet, Quek, Ooi, Sengupta, Lakshminarasappa et al., Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: an open-label randomized trial, Int. J. Infect. Dis,
doi:10.1016/j.ijid.2021.04.035Seipke, Kaltenpoth, Hutchings, Shahbaznejad, Davoudi et al., Effects of ivermectin in patients with COVID-19: a multicenter, double-blind, randomized, controlled clinical trial, FEMS Microbiol. Rev,
doi:10.1016/j.clinthera.2021.04.007Sharma, Ahmad Farouk, Lal, COVID-19: a review on the novel coronavirus disease evolution, transmission, detection, control and prevention, Viruses,
doi:10.3390/v13020202Shimizu, Hirata, Kabata, Tokuhira, Koide et al., Ivermectin administration is associated with lower gastrointestinal complications and greater ventilator-free days in ventilated patients with COVID-19: a propensity score analysis, J. Infect. Chemother,
doi:10.1016/j.jiac.2021.12.024Shoumann, Hegazy, Nafae, Ragab, Samra et al., Use of ivermectin as a potential chemoprophylaxis for COVID-19 in egypt: a randomised clinical trial, J. Clin. Diagn. Res,
doi:10.7860/JCDR/2021/46795.14529Tao, Zhang, Wang, Guo, Zeng et al., Analysis of the intestinal microbiota in COVID-19 patients and its correlation with the inflammatory factor IL-18, Med. Microecol,
doi:10.1016/j.medmic.2020.100023Xu, Cai, Shen, Ni, Chen et al., Management of corona virus disease-19 (COVID-19): the Zhejiang experience
Xuexuebao, Xue Ban, None, Zhejiang Univ. Med. Sci
Yeoh, Zuo, Lui, Zhang, Liu et al., Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19, Gut,
doi:10.1136/gutjnl-2020-323020Zhang, Albermann, Fu, Thorson, The in vitro characterization of the iterative avermectin glycosyltransferase AveBI reveals reaction reversibility and sugar nucleotide flexibility, J. Am. Chem. Soc,
doi:10.1021/JA065950KZubair, Chaudhry, Zubairi, Shahzad, Zahid et al., The effect of ivermectin on non-severe and severe COVID-19 disease and gender-based difference of its effectiveness, Monaldi Arch. Chest Dis,
doi:10.4081/monaldi.2022.2062Zuo, Wu, Wen, Lan, Gut microbiome alterations in COVID-19, Genomics Proteomics Bioinformatics
